LDL-Last über die Jahre: warum der Verlauf mehr zählt als ein Einzelwert

Low-density lipoprotein cholesterol (LDL-C) is a causal and modifiable driver of atherosclerotic cardiovascular disease and an important contributor to atherosclerotic ischemic stroke. Increasing evidence suggests that cumulative LDL-C exposure-the combined effect of LDL-C magnitude and duration over time-captures vascular injury more accurately than a single measurement obtained at one clinical encounter. This review uses cumulative LDL-C exposure as an organizing framework for stroke prevention. We summarize current approaches to quantifying long-term LDL-C burden, review epidemiological evidence linking cumulative exposure to incident and recurrent ischemic stroke, and discuss biological mechanisms that may explain these associations. We then examine how lipid-lowering therapies, including statins, PCSK9 inhibitors, and small-interfering RNA-based agents, may reduce cumulative vascular injury. Particular attention is paid to the clinical challenge of balancing ischemic benefit against potential hemorrhagic vulnerability in selected high-risk phenotypes, such as patients with probable cerebral amyloid angiopathy or multiple lobar cerebral microbleeds. We propose a precision-management framework that integrates longitudinal lipid exposure, stroke subtype, genetics, neuroimaging, and dynamic risk assessment. By shifting attention from static lipid values to lifelong exposure, cumulative LDL-C burden may offer a more coherent basis for individualized cerebrovascular prevention

Atherosclerotic cardiovascular disease (ASCVD) remains the leading global cause of morbidity and mortality, even in the era of aggressive low-density lipoprotein cholesterol (LDL-C) lowering. This persistent residual risk has prompted a reevaluation of atherogenic lipid markers, with non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (Apo B) emerging as superior indicators of the total atherogenic particle burden. Unlike LDL-C, non-HDL-C includes cholesterol from all atherogenic lipoproteins, while Apo B reflects the total number of atherogenic particles regardless of cholesterol content. Their clinical relevance is underscored in populations with diabetes, obesity, and hypertriglyceridemia, where LDL-C may not adequately reflect cardiovascular risk. This review explores the biological, clinical, and genetic foundations of non-HDL-C and Apo B as critical tools for risk stratification and therapeutic targeting. It highlights discordance analysis, inflammatory mechanisms in atherogenesis, the influence of metabolic syndromes, and their utility in specific populations, including those with chronic kidney disease and children with familial hypercholesterolemia. Additionally, the role of lipoprotein (a), glycation in diabetes, and hypertriglyceridemia are examined as contributors to residual risk. Clinical trials and genetic studies support Apo B and non-HDL-C as more robust predictors of cardiovascular events than LDL-C. Current guidelines increasingly endo

Apolipoprotein B (ApoB) has emerged as a central biomarker and mechanistic driver of atherosclerotic cardiovascular disease (ASCVD), outperforming traditional lipid metrics in both risk stratification and therapeutic targeting. In this article a critical evaluation of the information is presented on the molecular biology, metabolic regulation, and clinical relevance of ApoB isoforms, ApoB100 and ApoB48, which play their own distinct, yet complementary roles in hepatic and intestinal lipid transport. The ways in which ApoB particle density is influenced by insulin resistance, nutrient status, hepatic lipid flux, inflammation, and genetic variation, all of which contribute to dyslipoproteinemic phenotypes associated with ASCVD and metabolic syndrome. Importantly, ApoB levels provide a direct measure atherogenic particle number, offering superior predictive value over low-density lipoprotein cholesterol (LDL-C), particularly in cases of lipid discordance and among statin-treated patients with residual cardiovascular risk. Emerging evidence demonstrates therapies targeting ApoB reduction, including statins, PCSK9 inhibitors, and glucose-lowering agents such as GLP-1 receptor agonists, can significantly reduce major adverse cardiovascular events. However, the lipid-modulating effects of agents like SGLT2 inhibitors, metformin, and thiazolidinediones are variable or independent of ApoB changes. The classification of four ApoB-related dyslipoproteinemic phenotypes, normotriglyceride

<b>Background</b>: Physical activity (PA) is associated with cardiometabolic health and functional performance, but evidence from real-world primary care populations simultaneously examining PA, low-density lipoprotein cholesterol (LDL-C), and functional performance remains limited. <b>Objective</b>: This study evaluated associations between PA, LDL-C, and functional performance in a real-world primary care cohort. <b>Methods</b>: This cross-sectional observational study included 863 adult primary care patients evaluated between February 2021 and March 2026. The overall cohort had a mean age of 52.4 ± 14.8 years, and 53.3% of participants were female. PA was assessed using self-reported activity categories (low, moderate, or high) obtained during a routine clinical evaluation. LDL-C concentrations were analyzed in the full cohort, while Timed Up and Go (TUG) functional performance assessment was available in an exploratory subgroup (<i>n</i> = 214). Multivariable regression analyses were adjusted for age, sex, body mass index (BMI), diabetes mellitus, and arterial hypertension in the TUG analysis. <b>Results:</b> Higher PA categories were associated with lower LDL-C concentrations across groups (<i>p</i> < 0.001). Mean LDL-C concentrations were 3.68 ± 1.05 mmol/L in the low PA group, 3.39 ± 0.97 mmol/L in the moderate PA group, and 3.12 ± 0.89 mmol/L in the high PA group. In the exploratory TUG subgroup, higher PA categories were also associated with better functional perform